×
For best experience we recommend to activate Javascript in your browser.
Chemerin antibody (C-Term)
The Rabbit Polyclonal anti-Chemerin antibody has been validated for WB. It is suitable to detect Chemerin in samples from Human.
Quick Overview for Chemerin antibody (C-Term) (ABIN5620980)
Target
See all Chemerin (RARRES2) Antibodies
Chemerin (RARRES2)
(Retinoic Acid Receptor Responder (Tazarotene Induced) 2 (RARRES2))
Reactivity
All reactivities for Chemerin antibodies
Human
Host
All hosts for Chemerin antibodies
Rabbit
Clonality
All clonalities for Chemerin antibodies
Polyclonal
Conjugate
All conjugates for Chemerin antibodies
This Chemerin antibody is un-conjugated
Application
All applications for Chemerin antibodies
Western Blotting (WB)
Product Details anti-Chemerin Antibody
(hide)
Binding Specificity
All epitopes for Chemerin antibodies
C-Term
Specificity
Recognizes endogenous levels of TIG2 protein
Cross-Reactivity (Details)
Mouse, Rat
Characteristics
Purified Polyclonal TIG2 antibody
Purification
TIG2 antibody was purified by immunogen affinity chromatography
Immunogen
TIG2 antibody was raised in Rabbit using a KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human TIG2 as the immunogen
Alternatives
(show)
Application Details
(hide)
Application Notes
WB: 1:500 - 1:1000
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Buffer
Supplied in liquid form in 0.42 % Potassium phosphate, 0.87 % Sodium chloride, pH 7.3 with 30 % glycerol and 0.01 % sodium azide
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C/-20 °C
Storage Comment
Store at 4 deg C for short term storage. For long term, aliquot and store at -20 deg C. Avoid repeat freeze/thaw cycles
Target Details for Chemerin
(hide)
Target
Chemerin (RARRES2)
(Retinoic Acid Receptor Responder (Tazarotene Induced) 2 (RARRES2))
Alternative Name
TIG2
Pathways
Brown Fat Cell Differentiation
Recently viewed
(hide)
Chat with us , powered by LiveChat